期刊
INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 241, 期 -, 页码 344-350出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2017.02.018
关键词
Brain natriuretic peptide; Big endothelin-1; Eplerenone; Heart failure; Myocardial infarction; Biomarker change
资金
- Pfizer, Inc.
Objective: Increased levels of neuro-hormonal biomarkers predict poor prognosis in patients with acute myocardial infarction (AMI) complicated by left ventricular systolic dysfunction (LVSD). The predictive value of repeated (one-month interval) brain natriuretic peptides (BNP) and big-endothelin 1 (BigET-1) measurements were investigated in patients with LVSD after AMI. Methods: In a sub-study of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS trial), BNP and BigET-1 were measured at baseline and at 1 month in 476 patients. Results: When included in the same Cox regression model, baseline BNP (p = 0.0003) and BigET-1 (p = 0.026) as well as the relative changes (after 1 month) from baseline in BNP (p = 0.049) and BigET-1 (p = 0.045) were predictive of the composite of cardiovascular death or hospitalization for worsening heart failure. Adding baseline and changes in BigET-1 to baseline and changes in BNP led to a significant increase in prognostic reclassification as assessed by integrated discrimination improvement index (5.0%, p = 0.01 for the primary endpoint). Conclusions: Both increased baseline and changes after one month in BigET-1 concentrations were shown to be associated with adverse clinical outcomes, independently from BNP baseline levels and one month changes, in patients after recent AMI complicated with LVSD. This novel result may be of clinical interest since such combined biomarker assessment could improve risk stratification and open new avenues for biomarker-guided targeted therapies. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据